Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete or partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ Sustained remission/steroid sensitive relapses Clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: sustained… compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ CKD clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: CKD compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in adverse events: bacterial infections compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Number with complete remission: complete remission in initial steroid resistance · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Number with complete remission: complete remission in delayed steroid resistance · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in delayed… compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in all patients compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: bronchospasm/treatment discontinued · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: infection · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: infection compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse events: hypotension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse effects of antibiotics (skin rash) · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: skin rash compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: mild dyspnoea · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: mild dyspnoea compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: ESKD · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: ESKD compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete or partial remission compared with IV cyclophosphamide (low certainty).
1 finding from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete remission compared with IV cyclophosphamide (low certainty).
1 finding from 1 review
Major depression · people with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQoL Kidney Disease Quality of Life (KDQOL‐36) (median · people with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anxiety · people with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawal from dialysis · people with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found